ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says ASCO: BioNTech's Roche-partnered cancer vaccine combo hints at survival benefit in pancreatic cancer Yumanity's end: J&J pays $26M for neuroscience assets as reverse merger erases biotech Sponsored: Tech-Enabled Trials Don't Have to Mean Loss of Human Connection Biogen bets more than $700M on Alectos’ preclinical oral Parkinson’s drug to shore up pipeline Praxis acts fast as depression drug flunks late-phase test, stopping trials and reducing headcount ASCO: Adicet’s gamma delta CAR-T therapy readout paves way for pioneering phase 2 trial ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner? ASCO: Medidata links CAR-T's cytokine release syndrome risk to common biomarkers in new study Insilico gases up with $60M series D as the race to be the 'Formula One for Big Pharma' continues Immunic shifts back to multiple sclerosis focus after phase 2 ulcerative colitis effort fails ASCO: AstraZeneca, Daiichi’s Enhertu could transform breast cancer treatment with landmark HER2-low show AI is secret weapon for cancer trial recruitment and engagement, says TrialJectory CEO New mechanism behind biotech’s estrogen-targeting breast cancer drug opens the door for other hard-to-treat cancers Fierce Healthcare and Fierce MedTech's 17 rising stars in health tech Featured Story By Gabrielle Masson The numbers as they stand now don’t lie: Amgen’s Lumakras lasted longer than Mirati’s adagrasib in KRAS-mutated lung cancer. But Mirati's CEO still has high hopes for adagrasib, as an investigator of a study into the latecomer drug told Fierce Biotech that the two therapies have shown "essentially identical" efficacy. read more |
| |
---|
| Top Stories By Max Bayer BioNTech says early data of its Roche-partnered cancer combo shows promise in stemming the recurrence of pancreatic cancer. The early data of 16 patients found that half exhibited longer recurrence-free survival. read more By Nick Paul Taylor Yumanity Therapeutics has struck two agreements to erase itself from existence. Johnson & Johnson has stepped in to take on Yumanity’s lead program and unpartnered discovery-stage candidates, while Kineta has laid claim to its Nasdaq listing and Merck collaboration through a reverse merger. read more Sponsored by: Vault Health DCTs hold the promise of reducing site and patient burdens but at what cost to human connection? Vault says it doesn't have to be a compromise. read more By Max Bayer Biogen is looking to fortify the back end of its pipeline, betting more than $700 million on Alectos' preclinical oral Parkinson's med. The two companies will partner on the development of the asset until it's ready for the clinic, at which point Biogen will take the reins. read more By Nick Paul Taylor Praxis Precision Medicines’ challenge to Sage Therapeutics has unraveled. With a phase 2/3 clinical trial in major depressive disorder (MDD) failing comprehensively, Praxis is stopping work on a clutch of other studies, laying off staff and pinning its hopes on two other candidates. read more By James Waldron Adicet Bio’s gamble on the nascent gamma delta CAR-T cell therapy space seems to be paying off, with the latest phase 1 readout continuing showing the drug is safe and potentially effective. The biotech can now start to plan for a mid-stage trial of the pioneering medicine. read more By Annalee Armstrong Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for commercialization? read more By Annalee Armstrong As CAR T-cell therapy becomes more common in oncology, predicting the patients who may experience the life-threatening complication called cytokine release syndrome is becoming more important. Enter Medidata. read more By Max Bayer Insilico Medicine has closed a $60 million series D round to help propel its pipeline of more than two dozen wholly-owned assets towards the clinic. The latest fundraising haul follows a $255 million series C round in 2021, one of the largest of the year. read more By Annalee Armstrong Immunic’s lead asset may have been successful in multiple sclerosis, but it appears to be a dud in ulcerative colitis, where work will be discontinued. read more By Angus Liu A new era of breast cancer treatment may be upon us. With a landmark clinical trial win, AstraZeneca and Daiichi Sankyo could soon open up a brand-new breast cancer category and offer HER2-targeted therapy for many patients with what’s been traditionally characterized as HER2-negative disease. read more By Gareth Macdonald Artificial intelligence can remove barriers to participation, aid patient engagement and boost enrollment rates in cancer trials, according to an analysis by tech firm TrialJectory. read more By Gabrielle Masson Scientists have discovered a new target for killing off a variety of hard-to-treat cancer cells, opening the door for potential new drugs—an opening that biotech EtiraRx has already lodged its foot in. The new mechanism is targeting cancer types with high endoplasmic reticulum stress, such as triple-negative breast cancers (TNBCs), which are historically difficult to treat. read more By Conor Hale,Heather Landi Fierce Healthcare and Fierce Medtech compiled a list highlighting some of the biggest rising stars in the health tech industry, spanning the fields of artificial intelligence, software development and health IT. read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA @Philly Cell and Gene Therapy Annual Conference 2022 June 17-18th 2022; King of Prussia, PA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual |